Figure 1.

(a) Histology of the primary tumor: poorly differentiated adenocarcinoma (HE100X); immunohistochemistry: (b) ALK‐V (−), (c) ROS‐1(−) (100X); (d) PD‐L1 positive in the primary tumor sample (pretreatment surgical sample); (e) PD‐L1 negative in the metastatic tumor.